Bullish
Vertex Pharmaceuticals recently announced positive Phase 3 data for ALYFTREK and TRIKAFTA in younger pediatric cystic fibrosis patients, reinforcing i...
Bullish
Despite "death crosses" indicating bearish technical signals for Hershey (HSY) and Vertex Pharmaceuticals (VRTX), Wall Street analysts maintain a bull...
Bullish
Vertex Pharmaceuticals (VRTX) is focused on expanding its leadership in cystic fibrosis, pain, and renal disease. The company has a robust late-stage ...
Bullish
Vertex Pharmaceuticals is strengthening its position in the cystic fibrosis market through new pediatric ALYFTREK data, TRIKAFTA regulatory progress, ...
Bullish
Vertex Pharmaceuticals reported new clinical data for its cystic fibrosis therapy ALYFTREK in young children and detailed global regulatory submission...
Neutral
This article compares Kyverna Therapeutics and Vertex Pharmaceuticals as potential investments in 2026, highlighting their differing stages of develop...
Bullish
The Membranous Nephropathy (MN) market is projected for significant growth through 2036, driven by advancements in diagnosis, an increasing pipeline o...
Carmen R. Bozic, a securities compliance officer, reported multiple dispositions of Vertex Pharmaceuticals Inc. (VRTX) common stock through open-marke...
Vertex Pharmaceuticals (VRTX) has seen recent share price gains but a 3-month decline, yet its 5-year return remains strong. The stock is considered 1...
Bullish
Vertex Pharmaceuticals announced new data at the European Cystic Fibrosis Conference for its treatments ALYFTREK and TRIKAFTA. The data highlight the ...
Bullish
The acute pain market is projected to grow significantly from USD 4.5 billion in 2025 to USD 15.5 billion by 2036, driven by an increasing number of s...
Bullish
Vertex Pharmaceuticals announced that the FDA has accepted its Biologics License Application (BLA) for povetacicept, an investigational treatment for ...
Bullish
Vertex Pharmaceuticals announced that the U.S. FDA has accepted its Biologics License Application (BLA) for povetacicept for accelerated approval in a...
Bullish
The article identifies Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) as an "Affordable Growth" stock, combining strong growth metrics with reasonable valu...
Vertex Pharmaceuticals (VRTX) is expanding its franchises beyond Cystic Fibrosis (CF) into pain, hematology, and renal therapies, showing strong pipel...
Bullish
The Employees Retirement System of Texas has initiated a significant position of approximately USD 1.32 million in Vertex Pharmaceuticals Inc (VRTX), ...
Neutral
Vertex Pharmaceuticals' drug Journavx, despite being the first novel pain medicine approved by the FDA in decades, has not fully met initial sales pro...
Bullish
Dr. Reshma Kewalramani, President and CEO of Vertex Pharmaceuticals, has transformed the company into a formidable biotech player, achieving $12.0 bil...
Bullish
Vertex Pharma's stock is trading near record levels, driven by strong cash flows from its cystic fibrosis franchise and a promising late-stage pipelin...
Neutral
HighTower Advisors LLC raised its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 8.1% in the 4th quarter, Ho...